» Articles » PMID: 20713077

Fullerenol Cytotoxicity in Kidney Cells is Associated with Cytoskeleton Disruption, Autophagic Vacuole Accumulation, and Mitochondrial Dysfunction

Overview
Specialties Pharmacology
Toxicology
Date 2010 Aug 18
PMID 20713077
Citations 57
Authors
Affiliations
Soon will be listed here.
Abstract

Water soluble fullerenes, such as the hydroxylated fullerene, fullerenol (C₆₀OHx), are currently under development for diagnostic and therapeutic biomedical applications in the field of nanotechnology. These molecules have been shown to undergo urinary clearance, yet there is limited data available on their renal biocompatibility. Here we examine the biological responses of renal proximal tubule cells (LLC-PK1) exposed to fullerenol. Fullerenol was found to be cytotoxic in the millimolar range, with viability assessed by the sulforhodamine B and trypan blue assays. Fullerenol-induced cell death was associated with cytoskeleton disruption and autophagic vacuole accumulation. Interaction with the autophagy pathway was evaluated in vitro by Lysotracker Red dye uptake, LC3-II marker expression and TEM. Fullerenol treatment also resulted in coincident loss of cellular mitochondrial membrane potential and ATP depletion, as measured by the Mitotracker Red dye and the luciferin-luciferase assays, respectively. Fullerenol-induced ATP depletion and loss of mitochondrial potential were partially ameliorated by co-treatment with the autophagy inhibitor, 3-methyladenine. In vitro fullerenol treatment did not result in appreciable oxidative stress, as measured by lipid peroxide and glutathione content. Based on these data, it is hypothesized that cytoskeleton disruption may be an initiating event in fullerenol cytotoxicity, leading to subsequent autophagy dysfunction and loss of mitochondrial capacity. As nanoparticle-induced cytoskeleton disruption, autophagic vacuole accumulation and mitochondrial dysfunction are commonly reported in the literature, the proposed mechanism may be relevant for a variety of nanomaterials.

Citing Articles

Click Chemistry as an Efficient Toolbox for Coupling Sterically Hindered Molecular Systems to Obtain Advanced Materials for Nanomedicine.

Cabrera-Quinones N, Lopez-Mendez L, Cruz-Hernandez C, Guadarrama P Int J Mol Sci. 2025; 26(1.

PMID: 39795895 PMC: 11719597. DOI: 10.3390/ijms26010036.


Enhancing Therapeutic Efficacy in Cancer Treatment: Integrating Nanomedicine with Autophagy Inhibition Strategies.

Walweel N, Aydin O ACS Omega. 2024; 9(26):27832-27852.

PMID: 38973850 PMC: 11223161. DOI: 10.1021/acsomega.4c02234.


The impact of nanomaterials on autophagy across health and disease conditions.

Florance I, Cordani M, Pashootan P, Moosavi M, Zarrabi A, Chandrasekaran N Cell Mol Life Sci. 2024; 81(1):184.

PMID: 38630152 PMC: 11024050. DOI: 10.1007/s00018-024-05199-y.


Comparative Studies of the Structural and Physicochemical Properties of the First Fullerene Derivative FD-C (Fullerenol) and Second Fullerene Derivate SD-C (3HFWC).

Koruga D, Stankovic I, Matija L, Kuhn D, Christ B, Dembski S Nanomaterials (Basel). 2024; 14(5).

PMID: 38470808 PMC: 10935211. DOI: 10.3390/nano14050480.


The Second Derivative of Fullerene C (SD-C) and Biomolecular Machinery of Hydrogen Bonds: Water-Based Nanomedicine.

Matija L, Stankovic I, Puric M, Milicic M, Maksimovic-Ivanic D, Mijatovic S Micromachines (Basel). 2023; 14(12).

PMID: 38138321 PMC: 10745578. DOI: 10.3390/mi14122152.


References
1.
Hall J, Dobrovolskaia M, Patri A, McNeil S . Characterization of nanoparticles for therapeutics. Nanomedicine (Lond). 2007; 2(6):789-803. DOI: 10.2217/17435889.2.6.789. View

2.
Yamawaki H, Iwai N . Cytotoxicity of water-soluble fullerene in vascular endothelial cells. Am J Physiol Cell Physiol. 2006; 290(6):C1495-502. DOI: 10.1152/ajpcell.00481.2005. View

3.
Stern S, McNeil S . Nanotechnology safety concerns revisited. Toxicol Sci. 2007; 101(1):4-21. DOI: 10.1093/toxsci/kfm169. View

4.
Injac R, Perse M, Boskovic M, Djordjevic-Milic V, Djordjevic A, Hvala A . Cardioprotective effects of fullerenol C(60)(Oh)(24) on a single dose doxorubicin-induced cardiotoxicity in rats with malignant neoplasm. Technol Cancer Res Treat. 2008; 7(1):15-25. DOI: 10.1177/153303460800700102. View

5.
Monteiro-Riviere N, Inman A, Zhang L . Limitations and relative utility of screening assays to assess engineered nanoparticle toxicity in a human cell line. Toxicol Appl Pharmacol. 2008; 234(2):222-35. DOI: 10.1016/j.taap.2008.09.030. View